Black Diamond Therapeutics Inc
Black Diamond Therapeutics Inc (BDTX) Covered Calls
Black Diamond Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 86.51%, high versus the past year. BDTX's highest covered call setup is the $5.00 strike expiring Dec 17, 2027, sorted by theoretical annualized return. It's 240.14% out of the money with 399 days to expiration, a 243.54% return until expiration, and a 222.78% theoretical annualized return. Across the setups shown, annualized returns run from 14.94% to 222.78% at strikes between $1.50 and $5.00, with 216 to 399 days to expiration, as of Nov 13, 2026.
Read more
Running BDTX covered calls helps you generate income from Black Diamond Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best BDTX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If BDTX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling BDTX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given BDTX covered call is worth writing.
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations.
| 2027-12-17 | 399 | 5.00 | 240.14 | 0.05 | 1.05 | 358.00 | 243.54 | 222.78 | -3.40 | +0.57 | 316 | 1.00 |
| 2027-09-17 | 308 | 2.50 | 70.07 | 0.05 | 1.05 | 108.00 | 73.47 | 87.07 | -3.40 | +0.62 | 4 | 1.00 |
| 2027-12-17 | 399 | 2.50 | 70.07 | 0.15 | 1.15 | 118.00 | 80.27 | 73.43 | -10.20 | +0.67 | 0 | 1.00 |
| 2027-06-17 | 216 | 2.00 | 36.05 | 0.05 | 1.05 | 58.00 | 39.46 | 66.67 | -3.40 | +0.64 | 6 | 1.00 |
| 2027-09-17 | 308 | 2.00 | 36.05 | 0.10 | 1.10 | 63.00 | 42.86 | 50.79 | -6.80 | +0.67 | 0 | 1.00 |
| 2027-12-17 | 399 | 2.00 | 36.05 | 0.20 | 1.20 | 73.00 | 49.66 | 45.43 | -13.61 | +0.71 | 5 | 1.00 |
| 2027-12-17 | 399 | 1.50 | 2.04 | 0.35 | 1.35 | 38.00 | 25.85 | 23.65 | -23.81 | +0.79 | 0 | 1.00 |
| 2027-09-17 | 308 | 1.50 | 2.04 | 0.20 | 1.20 | 23.00 | 15.65 | 18.54 | -13.61 | +0.74 | 0 | 1.00 |
| 2027-06-17 | 216 | 1.50 | 2.04 | 0.10 | 1.10 | 13.00 | 8.84 | 14.94 | -6.80 | +0.70 | 9 | 1.00 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank86.51% High
- Market cap (M$)84
- 52 weeks high-67.19%
- 52 weeks low-2.65%
- Analyst recommendationStrong Buy
1.38 - Target price$11.00
648.30% above the current stock price - Dividend—
- Payout ratio0.00%
- Earnings date2026-11-10
- P/E—
- Future P/E—
- EPS (ttm)-0.77
- EPS growth next 5 years—
As of Nov 13, 2026